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Abstract
Background: Natural antibodies directed at carbohydrates reject porcine xenografts. They are initially
expressed in germline configuration and are encoded by a small number of structurally-related germline
progenitors. The transplantation of genetically-modified pig organs prevents hyperacute rejection, but
delayed graft rejection still occurs, partly due to humoral responses. IgVH genes encoding induced
xenoantibodies are predominantly, not exclusively, derived from germline progenitors in the VH3 family.
We have previously identified the immunoglobulin heavy chain genes encoding VH3 xenoantibodies in
patients and primates. In this manuscript, we complete the structural analysis of induced xenoantibodies
by identifying the IgVH genes encoding the small proportion of VH4 xenoantibodies and the germline
progenitors encoding xenoantibody light chains. This information has been used to define the
xenoantibody/carbohydrate binding site using computer-simulated modeling.
Results: The VH4-59 gene encodes antibodies in the VH4 family that are induced in human patients
mounting active xenoantibody responses. The light chain of xenoantibodies is encoded by DPK5 and
HSIGKV134. The structural information obtained by sequencing analysis was used to create computer-
simulated models. Key contact sites for xenoantibody/carbohydrate interaction for VH3 family
xenoantibodies include amino acids in sites 31, 33, 50, 57, 58 and the CDR3 region of the IgVH gene. Site-
directed mutagenesis indicates that mutations in predicted contact sites alter binding to carbohydrate
xenoantigens. Computer-simulated modeling suggests that the CDR3 region directly influences binding.
Conclusion: Xenoantibodies induced during early and delayed xenograft responses are predominantly
encoded by genes in the VH3 family, with a small proportion encoded by VH4 germline progenitors. This
restricted group can be identified by the unique canonical structure of the light chain, heavy chain and
CDR3. Computer-simulated models depict this structure with accuracy, as confirmed by site-directed
mutagenesis. Computer-simulated drug design using computer-simulated models may now be applied to
develop new drugs that may enhance the survival of xenografted organs.
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Xenoantibodies represent a subset of natural antibodies
that are present in normal humans as a consequence of
our natural immune defense to infectious agents. These
antibodies are evolutionarily conserved and can be classi-
fied into small groups on the basis of binding specificity
and canonical structure [1,2]. The majority of xenoanti-
bodies that initiate the rejection of porcine xenografts
obtained from wild-type donors are specific for the α-gal
epitope (Gal α1-3Galβ1-4GlcNAc-R) [3,4]. In normal
humans, non-human primates and galactosyltransferase
knockout mice, these antibodies are encoded by a small
number of germline genes [5-10]. The availability and
design of genetically-engineered donor organs has more
recently led to the opportunity to study humoral
responses that initiate acute xenograft rejection. Xenoanti-
bodies mediating this process in response to placement of
hDAF-transgenic organs are encoded by germline progen-
itors that are identical to those encoding xenoantibodies
induced in response to wild-type pig organs, albeit at a
delayed tempo [6,9,10,27]. In humans and non-human
primates, these germline progenitors are alleles of IGHV3-
11 [6,9,10]. In galactosyltransferase-deficient mice, a
clonal expansion of antibodies encoded by the germline
progenitor VHJ606 occurs following graft placement [8].
The molecular basis for this restriction is not understood.
Genetically-modified donor organs do not induce hyper-
acute rejection, but acute vascular rejection still occurs
[11-16]. The possibility that alternative carbohydrates
may be relevant targets of induced antibody responses to
genetically-modified xenografts has raised an interest in
the structure and functional characteristics of anti-carbo-
hydrate antibodies [13-19]. Natural xenoantibodies are
encoded by a small number of germline progenitors with
affinities for the gal carbohydrate that vary substantially
[20-23]. The avidity of these antibodies for the gal carbo-
hydrate does not increase following perfusion through
porcine livers [20,21] but xenoantibodies produced in
patients exposed to porcine islets do demonstrate an
increase in affinity for the gal carbohydrate over time [22].
Natural antibodies and induced xenoantibodies in
baboons do not differ in affinity for the gal carbohydrate
[23], but rodent monoclonal anti-carbohydrate antibod-
ies with mutations and a higher affinity for the gal carbo-
hydrate can reject xenografts at an accelerated tempo [24].
The association between xenoantibody structure, somatic
mutation and function during the progression of the
immune response, in vivo, remains unclear. It has been
postulated that the canonical structure of the germline
progenitor plays a key role in the specificity of select anti-
bodies for carbohydrates [25]. High resolution crystallog-
raphy has shown that anti-carbohydrate antibodies in
germline configuration can recognize a range of structur-
ally-related carbohydrate epitopes [26]. Antibodies that
bind to gal and structurally-related non-gal carbohydrates
may therefore be encoded by the same group of germline
progenitors. The relevance of this to the xenoantibody
response is that accurate structural information defining
xenoantibodies may be used to identify small molecular
inhibitors that target anti-carbohydrate xenoantibodies
and may enhance xenograft survival in multiple settings
in which induced antibody-mediated responses prevent
long-term graft survival.
Our laboratory has defined a select, restricted usage of
IgVH genes that encode xenoantibodies in multiple set-
tings. These antibodies have a unique canonical structure
that is conserved across species [6,9,10,27]. By performing
a detailed analysis of the sequence of IgVH genes encoding
xenoantibodies expressed in patients and large animals
mounting active immune responses to pig cells, an under-
standing of the three dimensional configuration of the
xenoantibody/gal binding site can now be determined. In
addition, sites of recurring mutations in vivo can be placed
in context of carbohydrate/xenoantibody binding sites
that can be predicted using computer-simulated models.
This information provides a novel and important link in
the development of reagents that can block anti-carbohy-
drate xenoantibodies that induce xenograft rejection.
In this manuscript, the structural basis of carbohydrate/
xenoantibody interaction has been defined by sequence
information comparing germline and mutated xenoanti-
bodies. A computer-simulated model has been generated
to define the unique structure of induced xenoantibodies
in humans and non-human primates. Specific sites rele-
vant for optimal xenoantibody/carbohydrate interaction
have been identified and the role of somatic mutation in
vivo at these sites during induced antibody responses can
now be studied to provide insight on the role of muta-
tions in the progression of the xenoantibody response.
Our data suggest that the configuration of the xenoanti-
body binding pocket of the small group of IgM antibodies
expanded during hyperacute and acute rejection
responses is similar. Five contact sites within the heavy
chain and the CDR3 region play a role in optimal xenoan-
tibody/gal carbohydrate binding.
Results
Exposure of patients to pig cells stimulates an increase in 
the expression of antibodies encoded by the VH4-59 
germline progenitor
We have used an anchor-ELISA PCR analysis to demon-
strate that xenoantibodies are predominantly encoded by
genes in the in the VH3 family and a smaller proportion of
these antibodies are encoded by genes in the VH4 family
[6,10]. The production of cDNA libraries from the periph-
eral blood of patients mounting active xenograft
responses has allowed us to apply colony filter hybridiza-Page 2 of 19
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progenitors encoding these antibodies. We identified the
IGHV3-11 and IGHV3-74 germline genes as the progeni-
tors of xenoantibodies produced by the VH3 family of
immunoglobulin genes, however the progenitors encod-
ing xenoantibodies in the VH4 family were not previously
identified. To complete the structural analysis of immu-
noglobulin genes encoding xenoantibodies, we produced
five VH4 cDNA libraries from peripheral blood samples
obtained from patients mounting active xenoantibody
responses to pig cells. The cDNA libraries were used to
determine whether an increase in gene expression associ-
ated with any of the germline progenitors in the VH4 fam-
ily could be identified when comparing Ig gene usage in
patients prior to and following exposure to pig cells. On
the basis of immunoglobulin gene sequencing of 48 genes
in each library, the relative expression of the VH4-59
germline gene was increased from 5–8% at day 0 to 43–
44% at day 10 post-xenoantigen exposure. The nucleotide
and animo acid sequence of six of these genes is shown in
Figure 1. The genes encoding IgM xenoantibodies in the
VH4 family, similar to those encoding VH3 xenoantibod-
ies, are expressed in germline configuration. We have pre-
viously reported that xenoantibodies encoded by the VH3
family are structurally-related and can be placed in one of
seven structural classes of immunoglobulin genes [6].
Xenoantibodies in the VH4 family are characterized by a 1-
1 canonical structure. This data indicates that the shape of
the binding pocket of this small group of antibodies dif-
fers from that encoded by the IGHV3-11 germline genes.
The DPK5 and HSIGKV134 germline genes are used to 
encode the light chain of xenoantibodies
In humans and non-human primates, a restricted group of
genes encodes the heavy chain of xenoantibodies, but
information on light chain genes is very limited. Due to
insufficient sequence information, the determination as
to whether a similar restriction in light chain gene usage
occurs cannot be made, nor can accurate molecular mod-
els of xenoantibodies be generated. We have previously
shown that xenoantibodies encoded by the IGHV3-11
IgVH germline progenitor can bind to the gal carbohydrate
when paired with the DPK9 light chain gene [6]. In non-
human primates, the light chain genes encoding xenoan-
tibodies have not been defined. We therefore prepared
cDNA libraries from peripheral blood samples of non-
human primates mounting active xenoantibody
responses following exposure to porcine hepatocytes or
heart xenografts. Our earlier studies showed that the
IGHV3-11 germline progenitor encodes xenoantibodies
in these non-human primates [9,10], and the same sam-
ples were now used to identify the light chain genes
expressed at this time. Serum samples were initially used
to verify that an induced xenoantibody response could be
documented by ELISA and cells were used to produce a
series of cDNA libraries [10]. We prepared 6 cDNA librar-
ies from rhesus monkeys prior to and at day 21 following
exposure to pig cells to identify the germline progenitors
encoding light chains. The relative frequency of Ig gene
usage by individual germline progenitors was determined
by sequencing 40 random clones from each library. The
results indicate that xenoantibodies expressed at day 21
were encoded by a restricted number of germline progen-
itors. The closest matching human germline genes were
DPK5 and HSIGKV134 in the VK I family (Figures 2 and 3
respectively). The closest matching germline sequences in
the rhesus monkey were IgKV1f and IgKV1z which
showed 95% and 93% nucleic acid sequence homology
with the day 21 post-transplant rhesus monkey genes
encoding xenoantibodies [28]. To date, little information
is available on VH and VL germline genes in non-human
primates. The rhesus germline light chain genes are mem-
bers of the V kappa 1 subgroup and are of the same canon-
ical structural class as human light chain genes encoding
single chain antibodies that bind to the gal carbohydrate.
The same germline progenitors were used to encode light
chains in xenoantibodies induced following immuniza-
tion with porcine hepatocytes or transplantation with
porcine heart xenografts. This information was used in the
computer-simulated model to complete our analysis of
the binding site configuration in xenoantibodies selected
for expansion in primates.
Computer-simulated modeling of the xenoantibody/gal 
binding pocket
The structure of the binding site was addressed using com-
puter-simulated molecular models generated by homol-
ogy modeling (Figure 4). Computer-assisted homology-
based modeling provides a reliable method of defining
the three-dimensional structure of the binding pocket of
xenoantibodies. Using this methodology, antibodies
whose structure has been defined by crystallography can
be used as a template for structural studies on an antibody
of interest. Three-dimensional structural data obtained by
modeling with homology-based techniques agrees well
when compared with data determined by x-ray crystallo-
graphic techniques [32]. We used the AUTODOCK and
DOCK programs for our model to identify contact sites
relevant for xenoantibody binding to the gal carbohydrate
(Arthur Olson, La Jolla, CA), [33,34]. Key contact sites rel-
evant for optimal xenoantibody/gal carbohydrate interac-
tion were identified by docking the gal carbohydrate in
trisaccharide and pentasaccharide forms into the compu-
ter-simulated model of the IGHV3-11 xenoantibody.
Energy scores were computed and the model selected on
the basis of the lowest energy conformation. The results of
the computer-assisted model indicate that the light chain,
heavy chain and CDR3 region each contribute to gal sac-
charide binding. Key contact sites include positions 31and
33 of the CDR1, 50, 57 and 58 of the CDR2, and 99–103Page 3 of 19
(page number not for citation purposes)
BMC Immunology 2007, 8:3 http://www.biomedcentral.com/1471-2172/8/3
Page 4 of 19
(page number not for citation purposes)
Nucleotide sequences of the VH genes encoding xenoantibodies in the VH4 familyFigure 1
Nucleotide sequences of the VH genes encoding xenoantibodies in the VH4 family. The IGVH4-59 germline progen-
itor encodes a proportion of xenoantibodies in patients mounting active xenoantibody responses. Shown are the sequences of 
immunoglobulin genes encoding xenoantibodies in patients at day 10 after placement on a bioartificial liver containing porcine 
hepatocytes. (A.) The nucleic acid sequence of genes encoding xenoantibodies in the VH4 family are most closely related to 
the human VH4-59 germline gene.Stars indicate identities in nucleic acid sequence. Clone numbers are indicated in parenthesis. 
Nomenclature of the germline genes, alignments and numbering are based on the human immunoglobulin germline gene table 
[68]. (B.) Translated amino acid sequences of VH4 genes encoding xenoantibodies compared with the amino acid sequence of 




          |----------------------------------------------------------------------------------------| 
VH4-59    CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGT 
(21)      ***************************************T********************************************C***** 
(29)      ***************A******************************G******************************************* 
(5)       ****************************************************************************************** 
(23)      ************G***************************************************************************** 
(7)       ****************************************************************************************** 
(11)      **************************************************************T*************************** 
 
            CDR1                        FR2                          CDR2 
                       |----------------------------------------| 
VH4-59    AGTTACTACTGGAGCTGGATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGTATATCTATTACAGTGGGAGCACCAACTACAAC 
(21)      *A************T*****************GA*******G*****A********C******************CTGT***********   
(29)      ****************************************************************************************** 
(5)       ****************************************************************************************** 
(23)      *************************************************************G**************************** 
(7)       ****************************************************************************************** 
(11)      *********************************************************************************TT******* 
                 
         FR3 
                |----------------------------------------------------------------------------- 
VH4-59    CCCTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCTGCGGACACG 
(21)      *******************************************T*******C***********T****T********T**C********* 
(29)      ****************************************************************************************** 
(5)       ****************************************************************************************** 
(23)      **T*****************************************************************************C**A****** 
(7)       ****************************************************************************************** 
(11)      ****************************************************************************************** 
 
                    FR3 
          --------------------| 
VH4-59    GCCGTGTATTACTGTGCGAGA 
(21)      ********************* 
(29)      ********************* 
(5)       ********************* 
(23)      ********************* 
(7)       *******************C* 
(11)      ********************* 
 
 
B.     
                       FR1                  CDR1           CDR2              FR3 
          |----------------------------|     |------------|                |--------------------      
VH4-59    QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADT 
   (21)   *************S**************L*N**********R*************TV***************M*H***************    
   (29)   ******************************************************************************************     
   (5)    ******************************************************************************************   
   (23)   ****E*********************************************S***************************************    
   (7)    *************************************************************************************T****      
(11) **************************************************VS***************S****S*******R***M*****  
 
              FR3 
          ------| 
VH4-59    AVYYCAR 
   (21)   *******       
   (29)   ******* 
   (5)    ******* 
   (23)   ******* 
(7) ******T  
(11)   ******* 
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The nucleotide and animo acid sequence of light chain genes encoding xenoantibodies induced in non-human primatesFigure 2
The nucleotide and animo acid sequence of light chain genes encoding xenoantibodies induced in non-human 
primates. (A.) The nucleotide sequence of genes encoding the light chain of xenoantibodies are most similar to the human 
HSIGDPK5 and HSIGKV134 germline genes. The sequences shown here are aligned with the human HSIGDPK5 germline gene 
as well as to the closest germline progenitor identified in non-human primates, IGKVIz. The sequence of the genes encoding 
the light chain of xenoantibodies at day 21 is compared with that at day 0. Clone numbers are indicated in parenthesis. (B.) 




                                            FR1  
               |----------------------------------------------------------- 
HSIGDPK5       GACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACC  
IGKVIz         **************************G***C*********************A*******    
D0(8)          ********************************C*******************A******T 
D0(15)         ********************************T*******************A******* 
D21(7)         ****************************GGC*T*************************** 
D21(15)        ****************************GGC*T*******************C******* 
D21(20)        **************************C**AC*T*************************** 
 
                                      CDR1                       FR2 
               --------|                                 |----------------- 
HSIGDPK5       ATCACTTGTCGGGCGAGTCAGGGTATTAGCAGCTGGTTAGCCTGGTATCAGCAGAAACCA  
IGKVIz         ********C**A**C********************************************* 
D0(8)          ********C**A**C******A*****CA******************************* 
D0(15)         *******AC**A**C********************************************* 
D21(7)         ********C**A**C****************AA********A****************** 
D21(15)        ********C**A**C****************AA********A****************** 
 
                           FR2                    CDR2              FR3 
               --------------------------|                     |----------  
HSIGDPK5       GGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCA  
IGKVIz         ***************************AAG**G**********C**************** 
D0(8)          ****G***********************G***G********A****************** 
D0(15)         *****************************************A****************** 
D21(7)         ***************************AAG************G***************** 
D21(15)        ************************************************************ 
 
                                              FR3 
               ------------------------------------------------------------ 
HSIGDPK5       AGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCT 
IGKVIz         ********T********************A****************************** 
D0(8)          **************************G**A*A**************************** 
D0(15)         ********T*****************G**A****************************** 
D21(7)         ************G*****************************T***************** 
D21(15)        ****************************G**A****T*********A************* 
  
                           FR3                                  
               -----------------------|                       
HSIGDPK5       GAAGATTTTGCAACTTACTATTGT 
IGKVIz         *****************T**C*** 
D0(8)          *****************T****** 
D0(15)         *****************T**C*** 
D21(7)         *************T********** 





         |--------FR1----------|    CDR1     |------FR2-----|  CDR2    
DPK5     DIQMTQSPSSVSASVGDRVTITC RASQGISSWLA WYQQKP GKAPKLLIY AASSLQS 
IGKV1z   **********L******K***** *********** ****** ********* K****A* 
D0(8)    *****************K***** ****D*HT*** ****** *R******* G****** 
D0(15)   *****************K****Y *********** ****** ********* ******* 
D21(7)   *********************** *******K*** ****** G******** K**N*E* 
D2115)   *****************T***** *******K*** ****** ********* ***T*** 
 
          |-----------FR3----------------|    
DPK5    GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC  
IGKV1z  *************E******************  
D0(8)   *************EY*****************  
D0(15)  *************E******************  
D21(7)   ********G*********F*********I*** 
D21(15)  *************GY*F**N******V*****  
BMC Immunology 2007, 8:3 http://www.biomedcentral.com/1471-2172/8/3of the CDR3. Positions 32 and 49 of the light chain also
contribute to optimal binding to gal tri and pentasaccha-
ride. Induced xenoantibodies and antibodies that demon-
strate the ability to bind to carbohydrates have a
structurally-similar binding pocket (Figure 4, [35,36]).
Interestingly, mutations identified in vivo in IgG xenoanti-
bodies expressed in patients undergoing active xenoanti-
body responses occur at several predicted contact sites
(Table 1, Figure 5). Mutations located in positions 50, 57
and 58 in the heavy chain of IgG xenoantibodies were
identified in both humans and non-human primates
mounting active xenoantibody responses (Figure 5,
[9,10]).
The affinity of xenoantibodies for the gal carbohydrate 
can be altered by site-directed mutations
The CDR1 region, identified as important for xenoanti-
body/gal carbohydrate interaction in the molecular
model, is identical in xenoantibodies induced in patients
and non-human primates [5-8]. Interestingly, the CDR1
sequence of the anti-gal monoclonal antibody 22.121 that
identifies the residual gal carbohydrate encoded by the
iGb3S gene following knockout of the galactosyltrans-
ferase gene also utilizes this CDR1 region [7]. We selected
this site for site-directed mutagenesis to create a mutation
in position 31 (aspartic acid) in the xenoantibody
encoded by IGHV3-11 to address whether the affinity of
antigen/antibody interaction would be altered by this
modification. The replacement of an aspartic acid with a
serine residue was accomplished by overlap extension
PCR. The gene was sequenced to confirm that the correct
mutation was introduced in the desired location. Site-spe-
cific mutations were also introduced at sites 50 and 54
within the CDR2. Site 50 is frequently mutated in IgG
xenoantibodies expressed in patients and in non-human
primates (Figure 5, [6,9,10]). The ability of the mutated
antibodies to bind to gal and block human natural anti-
body binding to purified gal pentasaccharide was meas-
ured using an ELISA assay. The results show that the
introduction of a mutation in position 50 improved the
ability of the single chain antibodies to block human nat-
ural antibody binding to purified gal, whereas mutations
at other sites were less effective (Table 1, Figure 6).
Binding affinity is not altered by somatic mutations in IgG 
genes encoding xenoantibodies in patients following BAL 
treatment
IgM xenoantibodies directed at the gal carbohydrate in
human patients treated with a bioartificial liver hepatic
support device (BAL) containing pig cells are initially
expressed in the absence of somatic mutation [6]. IgG
xenoantibodies that are detected by day 21 demonstrate
mutations in approximately 67% of the clones sequenced.
These mutations were not localized to the CDR regions of
the antibodies [6]. Sites at which mutations were identi-
fied in vivo in libraries of IgG clones encoding xenoanti-
bodies at day 21 after xenoantigen exposure included
positions 35, 50, 56, 57 and 58 (Figure 5). The amino acid
substitutions resulting from these mutations included the
substitution of a serine with an asparagine residue at posi-
tion 35 (both uncharged and polar), a tyrosine for an
alanine or a phenylalanine at position 50 (substitution of
an uncharged polar side chain for a nonpolar side chain)
and changes at position 56 and 57 for neutral amino acids
which were either polar or non-polar. In order to study the
biological role of the occurrence of mutations that were
identified in antibodies produced in patients mounting
active anti-gal xenoantibody responses to pig cells, the
IgVH gene (IGHV3-11) in germline and somatically-
mutated forms was cloned from the peripheral blood of
patient samples and expressed as single chain xenoanti-
bodies using the vector (pHEN2) (Table 2, Figure 6). The
light chain gene used in these constructs was the DPκ9
germline progenitor (Figure 5). Single chain antibodies
encoded by IGHV3-11 bind to the gal carbohydrate in
vitro when expressed in germline configuration, indicating
Table 1: ScFv xenoantibodies constructed to study the role of mutations in xenoantibody/gal carbohydrate interaction
ScFv Antibody Clone Location of Mutations in Amino Acids Source of cDNA
122B IGHV3-11 patient d10 germline clone 58, 67 IgM human xenoantibody clone isolated at day 10
33 (IGHV3-11 with mutations) 28,35,37,50,52a,55,56,57 73, 74, 76, 77, 78, 94 IgG human xenoantibody clone isolated at day 21
193 (IGHV3-11 with mutations) 23,24,55,67,73,74,77,93 IgG human xenoantibody clone isolated at day 21
511 (IGHV3-11 site-directed mutation) 31,47 Site-directed mutagenesis of germline IGHV3-11 
clone in germline configuration
528 (IGHV3-11 site-directed mutation) 31 Site-directed mutagenesis to modify amino acid 
#31 in the IGHV3-11 clone expressed in patients at 
day 10.
50D (IGHV3-11 site-directed mutation) 50 Site-directed mutagenesis to modify amino acid 
#50 in the IGHV3-11 clone expressed in patients at 
day 10.
54D (IGHV3-11 site-directed mutation) 54 Site-directed mutagenesis to modify amino acid 
#54 in the IGHV3-11 clone expressed in patients at 
day 10.Page 6 of 19
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The sequence of the light chain genes encoding xenoantibodies in non-human primates that are most similar to the h man germline gene HSIGKV134Figur  3
The sequence of the light chain genes encoding xenoantibodies in non-human primates that are most similar 
to the human germline gene HSIGKV134. (A.) The nucleotide sequence of genes encoding the light chain of xenoanti-
bodies aligned with the human germline gene HSIGKV134 and the closest non-human primate germline gene, IGKVIf, is shown. 
The sequences of the genes encoding xenoantibody light chains at days 0 and 21 are compared. Clone numbers are indicated in 
parenthesis.(B.) The amino acid sequence of genes encoding the light chain of xenoantibodies. 
                            FR1 
               |-----------------------------------------------------------
HSIGKV134      GACATCCAGATGACCCAGTCTCCATCCTCACTGTCTGCATCTGTAGGAGACAGAGTCACC
IGKVIf         *****************************C********T*************A*******
D0(2)          ********************************T***************************
D0(20)         ********************************T*******************A*******
D21(9)         ********************************T*******************A*******
D21(18)        ********************************T*******************C*******
      CDR1                          FR2
--------|                                 |-----------------
HSIGKV134      ATCACTTGTCGGGCGAGTCAGGGTATTAGCAGCTGGTTAGCCTGGTATCAGCAGAAACCA
IGKVIf         ********C**A**C********C*******ATGCT************************
D0(2)          ********C**A************G*******A***************************
D0(20)         ********C**A************************************************
D21(9)         ********C**A**C*********G******A**************************** 
D21(18)        ********C**A************************************************
                        FR2                      CDR2              FR3
--------------------------|                     |-----------
HSIGKV134      GAGAAAGCCCCTAAGTCCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCA
IGKVIf         *G*************CT*******************************************
D0(2)          *G*************C***********AAG**************************T***
D0(20)         *G*************C***********AAG**************************CC**
D21(9)         *G*************C********************************************               
D21(18)        *G*************C***********AAG*******C**********************
                           FR3
------------------------------------------------------------
HSIGKV134      AGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCT
IGKVIf         ************************************************************
D0(2)          **************************G****A****************************
D0(20)         **A*******************************T*************************
D21(9)         *****************************A***************G**************
D21(18)        ************************************************************
                         FR3                   
-----------------------|         
HSIGKV134      GAAGATTTTGCAACTTATTACTGC
IGKVIf         ***********************T
D0(2)          ************G**********T 
D0(20)         **********T************T
D21(9)         ***********************T
D21(18)        ***********************T
B.
|--------FR1----------|    CDR1     |------FR2----|  CDR2
HSIGKV134  DIQMTQSPSSLSASVGDRVTITC RASQGISSWLA WYQQKPEKAPKSLIY AASSLQS
IGKV1f     *****************K***** *******NA** ******G****L*** *******
D0(2)      *********************** *****V*R*** ******G****P*** K******
D0(20)     *****************K***** *********** ******G****P*** K******
D21(9)     *****************K***** *****V*N*** ******G****P*** *****E*
D21(18)    *****************T***** *********** ******G****P*** K**T***
           |-----------FR3----------------|  
HSIGKV134  GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
IGKV1f     ********************************
D0(2)      **************Y*************A***  
D0(20)     ***P***********I***********V**** 
D21(9)     ********************G*********** 
D21(18)    ********************************  
A.
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Computer-simulated model of xenoantibody/carbohydrate interaction in humans and non-human primatesFigure 4
Computer-simulated model of xenoantibody/carbohydrate interaction in humans and non-human primates. 
(A.) Anti-carbohydrate single chain antibody (assession number IMFA) complexed with a trisaccharide carbohydrate antigen. 
Amino acids in key contact sites identified by crystallography are shown. The information can be accessed in the NCBI data-
base by homology search for structural similarities. (B.) The IGHV3-11 xenoantibody (122B) induced in human patients 
mounting an active immune response following placement on a bioartificial liver.  (C.) Computer-simulated model of the 
IGHV3-11 human single chain xenoantibody (122B) aligned with the VH4-59 germline progenitor (clone 5, Fig 1). (D.) The 
IGHV3-11 VH gene [9] and DPK5 light chain genes (clone 17, Fig 2) encode a xenoantibody expressed at high levels post-trans-





BMC Immunology 2007, 8:3 http://www.biomedcentral.com/1471-2172/8/3that specificity for this carbohydrate is inherent in the
binding pocket formed by the IGHV3-11 heavy chain and
DPk9 light chain. Soluble single chain xenoantibodies
expressed in germline and somatically mutated forms
were compared for their ability to bind to pig cells and
block human natural antibody binding to cells of xenoge-
neic origin (Table 2, Figure 7). Preincubation with soluble
antibodies results in inhibition of human natural IgM and
IgG antibody binding to pig endothelial cells, ranging
from 56–71%, as measured by flow cytometry. Germline
and somatically-mutated antibodies demonstrated no sig-
nificant differences in the ability of equivalent concentra-
tions of soluble single chain antibodies to block human
xenoantibody binding to pig cells (Table 2, Figure 7). The
relative affinity of the germline form of the antibody for
the purified gal carbohydrate in pentasaccharide form was
Amino acid translation of the sequences of genes encoding human xenoantibodiesFigure 5
Amino acid translation of the sequences of genes encoding human xenoantibodies. (A.) The amino acid translation 
of immunoglobulin heavy chain genes in the VH3 family encoding xenoantibodies at days 10 and 21 following exposure to por-
cine hepatocytes.  The sequences at day 10 are expressed in germline configuration, however, the sequences at day 21 demon-
strate the onset of mutations. Site-directed mutations were introduced into the germline gene in positions shown. (B.) The 
amino acid sequence of the genes encoding the light chain of a human xenoantibody that binds to the gal carbohydrate is 
shown compared with the closest germline progenitor, DPK9.
FR1 CDR1      FR2           CDR2
  |-----------------------------|      |-------------| 
   IGHV3-11     QVQLVESGGGLVKPGGSLRLSCAASGFTFS DYYMS WIRQAPGKGLEWVS YISSSGSTIYYADSVKG
   122B d10     ****************************** ***** ************** *********S*******
     33 d21     **************************D*** ****N *V************ A**G**GPT********
      6 d21     **************************D*** ****N ************** F**N**GYVK*******
    193 d21     **********************DS****** ***** ************** ******T**********
Site-directed mutations
   clone 50D    ****************************** ***** ************** D********S*******
   clone 54D    ****************************** ***** ************** *****D***S*******
   clone 528    ****************************** S**** ************** *********S*******
   clone 511    ****************************** S**** ***********G** *********S*******
   FR3
                |-------------------------------|
   IGHV3-11     RFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR
   122B d10     *C******************************
     33 d21     *C*****DS*STV*****************V*
      6 d21     *********NK**H*E**N***D***I****K
    193 d21     *******DS**T******************V*
 Site-directed mutations
  clone 50D     *C******************************
 clone 54D     *C******************************
  clone 528     *C****************************** 
  clone 511     *C******************************
       DPK9     DIQMTQSPSSLSASVGDRVTITC   RASQSISSYLN   WYQQKPGKAPKLLIY AASSLQSG
                ***L*******P***********   ***********   *************** ********
                VPSRFSGSGSGTDFTLTISSLQPE
                ************************  DFATYYCQQSYSTHTFGQGTKLEIK
A.
B.Page 9 of 19
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BMC Immunology 2007, 8:3 http://www.biomedcentral.com/1471-2172/8/31.1 × 10-8 M, compared with 2–4 × 10-8 M when 14 amino
acid substitutions were introduced during the evolution
of the immune response of antibodies encoded by the
IGHV3-11 germline progenitor (Figure 5, Table 2). The
affinity for the gal carbohydrate remained in the 10-8 M
range despite the presence of mutations in genes encoding
IgG xenoantibodies in these patients.
Discussion and conclusion
Xenoantibodies that initiate the rejection of porcine
xenografts are included under the broad classification of
"natural antibodies" in humans [3,4]. Natural antibodies
are believed to play a primary role in defense against path-
ogens before specific antibodies are produced by the
immune system. For many years, natural antibodies were
defined as polyreactive antibodies that bind to multiple
target antigens such as nucleic acids, proteins and polysac-
charides with low-to-moderate affinity [37-39]. More
recently, high-affinity, monospecific natural antibodies
have been identified that bind to a single target with
kinetic constants similar to those observed for immune
antibodies. Monospecific natural antibodies may be
expressed in germline configuration [40], raising the
intriguing possibility that the specificity of groups of nat-
ural antibodies is inherent in the structural configuration
of the binding site [2,41].
Our laboratory has been studying the structure, sequence,
and germline origin of xenoantibodies in several models
of xenograft rejection. A small number of closely-related
Ig genes that are evolutionarily conserved in structure
encode xenoantibodies when expressed in germline con-
figuration in all species studied to date [6,7,9,10,42,43].
The repertoire of pre-existing anti-gal antibodies that is
present in normal individuals in the absence of immune
stimulation, has been demonstrated in several experimen-
tal settings to include antibodies encoded by a relatively
small number of germline progenitors. Knockout mice
and patients mounting active immune responses to por-
cine xenografts demonstrate a selective expansion of anti-
gal antibodies encoded by one or two germline progeni-
tors from the available repertoire [6-10]. The molecular
basis for the expansion of xenoantibodies encoded by
selected germline progenitors from a larger repertoire of
pre-existing natural xenoantibodies with the ability to
bind to the gal carbohydrate is not understood. Clarifica-
tion of the structural requirements for optimal xenoanti-
body gal/carbohydrate interaction may provide insight
into the process by which xenoantibodies that mediate
the rejection of porcine xenografts are recruited. Further-
more, this information may be directly used to develop
new strategies or optimize existing strategies for prevent-
ing xenoantibody/carbohydrate interaction [44-46].
In humans, anti-gal xenoantibodies are predominantly
encoded by a small group of VH3 genes [6,7]. Antibodies
selected for expansion in patients mounting anti-gal
responses can be classified into one of the seven canonical
structural groups for IgVH genes [29,30], and display a
well-defined structural conformation of the binding
pocket. The evolutionary conservation of antibodies with
this structure suggests they play a role in host defense
[31,41,47]. The presence of the gal carbohydrate on cer-
tain types of enteric bacteria provides a basis for the selec-
tion, retention, and redundance in the ability of the
immune system to initiate an antibody response with this
defined specificity [47]. We have established that somatic
mutation is not required for xenoantibody binding to the
gal carbohydrate [6]. IgG xenoantibodies induced in
humans at day 21 post-BAL display mutations that are
neither localized in the CDR regions of the xenoantibod-
ies nor do they significantly enhance the binding of
xenoantibodies to purified gal pentasaccharide [48,6].
Mutations do not appear in key sites that determine the
canonical structure of anti-gal antibodies, or if they do
occur, are not selected for in xenoantibodies expanded in
response to pig cells [6]. This data is consistent with the
findings of Dehoux et al. who demonstrate that no signif-
icant difference in the affinity of natural antibodies that
mediate hyperacute rejection and those that initiate acute
vascular rejection of porcine kidney xenografts could be
demonstrated [23]. In these baboons, an isotype switch
occurs that is associated with an increase in all IgG sub-
classes, especially IgG1 but no increase in the affinity of
IgG xenoantibodies for the gal carbohydrate. Similarly,
Cotterell et al have reported that the avidity of human IgM
xenoantibodies before and after perfusion through por-
cine livers remains unchanged [49]. The affinity of
xenoantibodies that bind to the gal carbohydrate in
baboons and humans is generally between 1–4 × 10-8 for
IgM and IgG xenoantibodies, but may vary within the
range of 10-7 to 10-10 M as reported by several groups
Table 2: Percent inhibition of natural antibody binding to PAEC with ScFv antibodies
ScFv Antibody Clone Percent inhibition of IgM 
natural antibody binding
Percent inhibition of IgG 
natural antibody binding
Percent decrease in 
complement-mediated 
cytotoxicity to PAEC
Binding affinity (M) of 
xenoantibodies for gal 
saccharide
germline d10 56.8 +/- 4.5 69.6 +/- 5.4 20.4 +/- 4.4 1.1 – 1.6 × 10-8
mutated d21 52.8 +/- 3.2 71.4 +/- 4.5 18.5 +/- 5.5 2.3 – 4.2 × 10-8Page 10 of 19
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Single chain xenoantibodies were produced using the pHEN vector and expressed as soluble antibodiesF gur  6
Single chain xenoantibodies were produced using the pHEN vector and expressed as soluble antibodies.  The 
xenoantibodies with site-directed mutations were compared with the germline progenitor for the ability to inhibit natural anti-
body binding. (A.) The IGHV3-11 gene encoding xenoantibodies in human patients was cloned into the vector pHEN2.  Single 
chain xenoantibodies were expressed as phagemid or soluble antibodies for functional studies. (B.) The soluble antibodies 
were run on an SDS page gel to confirm that antibody was produced. (C.) The ability of the soluble single chain antibodies with 
specific site-directed mutations to block human xenoantibody binding was compared by inhibition ELISA. The ability to bind 
more efficiently to purified gal carbohydrate, and thereby block human xenoantibody binding more effectively was compared in 
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BMC Immunology 2007, 8:3 http://www.biomedcentral.com/1471-2172/8/3[5,21,23]. Antibodies produced in humans transplanted
with porcine islet cells demonstrate an increase in affinity
for the gal carbohydrate from 2 × 10-7 M to 1 × 10-8 M, sug-
gesting that an affinity maturation response occurred in
these patients over several months time [22]. Affinity mat-
uration may therefore not be evident in several settings
until sometime later than 3 weeks post-transplantation
[9-11], however in the interim, acute vascular rejection
can occur. Since affinity of natural anti-gal xenoantibodies
selected for expansion in human patients post-transplan-
tation is relatively high when expressed in germline con-
figuration in naïve individuals, our data suggests that
polyreactive xenoantibodies with binding affinities
within the order of 10-3 to 10-6 are not relevant for
xenograft reactions.
On the basis of this information, and sequence data
obtained from multiple models of xenograft rejection that
have been studied in our laboratory, we have formulated
the hypothesis that a unique structural configuration
(defined by the canonical structure of the immunoglobu-
lin light chain, heavy chain and CDR3 region) defines IgM
and IgG xenoantibodies directed at pig cells and/or
xenografts in the presence or absence of somatic mutation
[6]. The concept that the shape of an antigen binding site
is specialized to conform to specific types of antigen/anti-
body interactions, in general, was originally proposed by
Lara-Ochoa et al. [41]. Interestingly, recent studies have
indicated that although a potentially large combination of
canonical structures is possible, only a few are selected
and utilized in the human antibody repertoire [31]. Spe-
Xenoantibodies expressed in germline and somatically-mutated configurations demonstrate comparable abil-ity t  block human natural IgM and IgC xenoantibody binding to pig cellsFigure 7
Xenoantibodies expressed in germline and somatically-mutated configurations demonstrate comparable abil-
ity to block human natural IgM and IgC xenoantibody binding to pig cells. Xenoantibodies cloned from the periph-
eral blood of human patients mounting active xenoantibody responses were expressed as single chain xenoantibodies. The 
ability of xenoantibodies with mutations (clone 33) to block human natural antibody binding to pig cells was compared with 
that of the antibody expressed in germline configuration (clone 122B) by flow cytometry. The antibody expressed in germline 
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nations, only ten are preferentially used. The process of
molecular recognition, therefore, may begin with a basic
recognition of an antigen with a defined shape by small
numbers of germline progenitors with a specific main
chain structural conformation. This first stage of antigen/
antibody recognition, proposed to be the basis for the
evolutionary selection of small groups of structurally-
related antibodies, may provide an explanation for the
well-documented restriction in immunoglobulin genes
encoding xenoantibodies. Antigen/antibody interaction
initiated by binding to antibodies with a select main-
chain conformation, followed by a second stage of selec-
tion for antibodies with specific amino acids in key con-
tact sites within the hypervariable region sequence that are
relevant for optimal for xenoantibody/gal interaction is a
concept consistent with our data. In humans, anti-gal
antibodies in unimmunized individuals are encoded by a
group of 6–8 well-defined and structurally-related germ-
line progenitors [5]. Exposure to pig cells in humans,
monkeys or mice results in the selective expansion of
xenoantibodies encoded by one or two of these germline
genes [6-10]. The basis for this second stage of selection
may be clarified by a detailed analysis of the structure of
the xenoantibody/gal binding site [19]. Amino acids in
specific contact sites defined by computer-simulated
models may play a role in the selection of antibodies for
expansion. In other types of natural antibody/antigen
interactions, such as binding to single-stranded DNA and
insulin, single amino acid mutations have the ability to
significantly increase the affinity and/or alter the specifi-
city of the antibody [40]. Seemingly minor changes in
amino acids located in key contact sites relevant for
xenoantibody/gal carbohydrate interaction may dramati-
cally modify natural antibody responses. The identifica-
tion of key contact sites and the application of this
information to understanding the role of mutations in
xenoantibodies that mediate the rejection of porcine
xenografts would provide a solution to the controversy
regarding the functional role of mutations in delayed
xenograft rejection.
Although contact sites are best defined by crystallography,
computer-simulated modeling combined with site-
directed mutagenesis has been used successfully to define
the sites critical for antibody/antigen interaction [32,50].
The construction of engineered antibodies and three-
dimensional models representing antigen/antibody inter-
action defines the binding site of each unique antigen/
antibody interaction in a way that cannot be done using
sequence information alone. At the three-dimensional
level, the unique folding of CDR and framework segments
mutually influence each other's conformation. The struc-
tural repertoire of the CDR is characterized by a finite
number of main chain conformations, yet the differences
in key amino acids within the CDR contribute to the gen-
eration of a large number of antibodies with varied topol-
ogies. The wide diversity in antigen binding specificities is
attributed largely, but not exclusively, to variation in sur-
face features of the CDR [51-53]. Antigen binding
involves multiple non-covalent interactions between
atoms in the antigen and the CDR surface, although only
about one third to one fifth of the CDR surface partici-
pates directly in antigen contact [54]. The generation of
computer-simulated models provides a method to iden-
tify specific contact sites unique to each antibody/antigen
interaction. The information gathered from these models
is broadly applicable in antibody engineering, antigen
docking and in structure-based drug design.
We have applied computer-simulated techniques to create
a model of xenoantibody/gal carbohydrate interaction.
The model has identified xenoantibody/gal pentasaccha-
ride binding sites at positions 32 and 49 of the light chain,
31 and 33 of the CDR1, 50, 57 and 58 of the CDR2 and
99–103 within the CDR3 region of the heavy chain. Site-
directed mutagenesis at a single site was demonstrated to
alter the affinity of xenoantibody binding to the gal carbo-
hydrate, as suggested by the model, however, the affinity
of the xenoantibodies remain in the 10-8 M range in the
presence or absence of mutations in vivo. Functional anal-
ysis of anti-gal xenoantibodies cloned from cDNA librar-
ies prepared from the peripheral blood of patients
mounting active xenoantibody responses indicates that
high affinity xenoantibodies are not produced in vivo in
patients at day 21 following at least two exposures to pig
cells in the bioartificial liver hepatic support device.
Although this could be attributable to the method and/or
length of exposure of these patients to porcine cells, it is
equally possible that somatic mutation does not contrib-
ute to any appreciable increase in binding affinity for anti-
bodies that mediate the xenograft rejection response.
Precedent for the latter possibility has been shown to
occur in other types of antibodies that play a key role in
rapid defense responses, such as protective antibodies
produced in response to viruses and antibodies that medi-
ate human immune responses to Haemophilus influen-
zae b capsular polysaccharide [55,56]. Antibodies directed
at pathogenic agents with repetitive antigenic determi-
nants demonstrate high affinity binding determined
exclusively by specific germline VH and VL combinations
in the absence of mutations and have similar binding
affinities when expressed in germline and somatically-
mutated configurations [57]. Ongoing pressure therefore
exists to conserve the germline configuration of the varia-
ble region of these antibodies [58]. Our studies indicate
that xenoantibodies respond in a manner that is very sim-
ilar to other evolutionarily-selected antibodies that play a
role in innate defense.Page 13 of 19
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predicted by molecular models include amino acids
within the third complementarity determining region of
the heavy chain. The CDR3 is characterized by a large
diversity in amino acid composition and length. Classifi-
cation of these loops into canonical forms has been diffi-
cult due to this large variation in composition [52,53]. To
date, thirteen canonical forms have been defined for the
CDR3 region of immunoglobulin heavy chains. These
forms represent a combination of a specific take-off geom-
etry and specific apex, and are classified according to
sequence motif, intra-loop interaction and/or main chain
geometry. Although the loop take-off angle and specific
apex geometry are important for defining the structure of
the CDR3 segment, the plasticity of the antibody response
ensures that select conformational structures may be
achieved by multiple mechanisms. Our sequence infor-
mation and molecular modeling data suggests that the
CDR3 of xenoantibodies induced in response to exposure
to pig cells is restricted in structure and contributes to anti-
body specificity. Molecular modeling of the IGHV3-11
antibody docked to the gal carbohydrate indicates that
amino acids in positions 99–103 (EYLSS) are important
for xenoantibody/gal interaction. Consistent with most
antigen-antibody interactions, contacts at the end of the
loop closer to the center of the combining site contribute
to the specificity of xenoantibody/gal interactions. In
humans and non-human primates mounting active
xenoantibody responses, this CDR3 is selectively utilized
in xenoantibodies that are expanded in response to por-
cine hepatocyte, heart and islet transplantation [6,9,10].
In patients, VH and VL germline genes encoding antibodies
with a specific light chain, heavy chain and CDR3 are
recruited in response to pig cell exposure. Although this
pattern of antibody selection may be driven by a specific
type of xenoantigen presentation and/or the time of expo-
sure to porcine xenoantigens, a similar pattern of selection
has been defined in knockout mice exposed to solid organ
xenografts [8]. This restriction suggests that antibodies
binding to carbohydrates are further selected on the basis
of usage of specific CDR3 and J regions.
The significance of the xenoantibodies encoded by the
VH4-59 germline progenitor has yet to be determined.
Although xenoantibodies encoded by the IGHV3-11
germline progenitor encode most of the induced xenoan-
tibodies in humans and non-human primates mounting
active xenoantibody responses to xenografts from wild-
type pigs, the minor population of xenoantibodies
encoded by the VH4 family could bind to non-gal xenoan-
tigens. The determination as to whether these IgVH genes
are induced during delayed rejection of gal knockout
organs would provide insight as to whether xenoantibod-
ies directed at structurally-similar carbohydrates may play
a role in delayed rejection. The role of this group of anti-
bodies and the contribution of the complex CDR3 topog-
raphy to binding affinity and specificity are the subject of
ongoing studies in our laboratory.
Methods
RNA isolation
Total RNA was extracted from the peripheral blood lym-
phocytes obtained from human patients at days 0, 10 and
21 post-exposure to pig hepatocytes following placement
on a bioartificial liver [59] and from rhesus monkeys at
day 0 and 21 post transplantation with porcine heart
xenografts or post-immunization with porcine hepato-
cytes [9,10]. A strong IgM and IgG xenoantibody response
to pig endothelium and to the α-gal epitope was verified
by ELISA [6,9,10]. All procedures in non-human primates
were reviewed and approved by the Institutional Animal
Care and Use Committee at the University of California at
Davis. RNA extraction was performed using a solution
containing 4 M GuSCN, 1.5 M Na citrate (pH 7.0) and
0.5% sarcosyl. RNA was subjected to a phenol/chloro-
form/isoamyl alcohol extraction, precipitated with iso-
propanol, then resuspended in 1 mM EDTA pH 8.0 and
precipitated with 0.3 M sodium acetate and ethanol.
PCR for analysis of the immunoglobulin VH genes encoding 
xenoantibodies
Total RNA isolated from PBL derived from patients prior
to and following exposure to a bioartificial liver and non-
human primates immunized with porcine hepatocytes
and endothelial cells was used to prepare first strand
cDNA using a μ-chain-specific primer (GGGAAAAG-
GGTTGGGGCGGATGCA) or γ-chain specific primers
(GACCGATGGGCCCTTGGTGGA for human) and
(GGGTTGTAGTCCTTGACCAGGCAG for monkeys). The
cDNA/RNA hybrids were hydrolyzed with NaOH. A
nested PCR reaction was used to clone and analyze the
IgVH and IgVL genes that encode xenoantibodies [6]. The
framework primers used to clone IgM antibodies from the
IgVH 3 and 4 families were (GAGGTGCAGCTGGT-
GGAGTCTGG and CAGGTGCAGCTGCAGGAGTC),
respectively. Immunoglobulin gene products amplified in
the first PCR reaction using Cμ and anchor primers were
subjected to a nested reaction using Cμ primer #3 and a
VH3 or VH4 gene family-specific primer containing an SfiI
restriction site at the 5' end. The PCR was performed in a
Perkin-Elmer 9600 GeneAmp PCR System Thermocycler
for 1 cycle of 94°C 5 min., 30 cycles of 94°C for 45 sec-
onds, 56°C for 60 seconds, 72°C for 90 seconds, and one
cycle of 72°C for 7 minutes. The primers used to amplify
immunoglobulin kappa light chain genes were kappa 4
(ACAGATGGTGCAGCCACAG) and kappa 5 (CAGAT-
GGCGGGAAGATGAAG) which align with the Cκ gene
and primers KJ04 (ATTGTAATGACACAG) and KJ05 (TCT-
GCATCTGTAGGAGAC) which align with the Framework
1 region of the light chain. The PCR products were verifiedPage 14 of 19
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vector (Invitrogen, San Diego, CA). The cloned DNA was
transformed into E. coli, and recombinant colonies iden-
tified for plasmid preparation on the basis of color screen-
ing. PCR products were ligated into the pCR 2.1 vector
(Invitrogen, Carlsbad, CA) and transformed into INVαF'
cells. A minimum of 40 colonies from each library were
sequenced to establish the IgVH genes encoding antibod-
ies by specific germline progenitors.
Expression of the cDNA clones as single chain antibodies
Immunoglobulin genes encoded by the IGHV3-11 germ-
line progenitor display an increased frequency of expres-
sion in B cells isolated from the humans and non-human
primates mounting active xenoantibody responses. These
genes, expressed in germline and somatically-mutated
configurations were cloned into the single chain antibody
expression vector (pHEN2, Center for Protein Engineer-
ing, Medical Research Council Centre, Cambridge, Eng-
land). Single chain antibodies were used in flow
cytometry experiments and ELISA to measure binding spe-
cificity for purified α-gal carbohydrate and for pig
endothelial cells. Briefly, cloning was accomplished by
amplification of the IGHV3-11 cDNA clones in a PCR
reaction using the primers VH3 Back Sfi
(GTCCTCGCAACTGCGGCCCAGCCGGCCAT-






TACTCAGGTACTCTCGC), and JH3 2
(TGAAGAGACGGTGACCATTGTCCCTTGGCCCCAGA-
TATCAAAAGCAT). The PCR products were gel purified
and ligated into the pHEN2 vector which had been
restricted with the enzymes Sfi I and Xho I. The ligation
was transformed into competent bacteria and screened
using a VH3 primer and JH3 primer to check for the insert.
Phagemid containing the cloned genes were grown in
2XTY containing 100 μg/ml ampicillin and 1% glucose
and were infected with VCSM13 helper phage (Strategene
Cloning Systems, La Jolla, CA) at a ratio of 1:20 (number
of bacterial cells:helper phage). The infected cells were
then grown in 2XTY containing 100 ug/ml ampicillin and
25 ug/ml kanamycin overnight at 30°C. The phage were
precipitated with polyethylene glycol 6000/NaCl (20%
PEG, 2.5 M NaCl), titered, and resuspended in PBS to 1013
transducing units/ml. Nucleic acid sequencing was used
to confirm that no additional nucleic acid substitutions
were introduced into the cDNA clones during the PCR
reaction used to modify the ends of the clones for compat-
ibility with the phagemid vector. 109–1012 phage were
used in ELISA assays to measure binding specificity for the
gal carbohydrate [6].
Screening phage particles by ELISA
The binding of phage particles expressing the IGHV3-11
germline gene as a single chain antibody to mouse lam-
inin was addressed using Falcon Microtest III flexible
assay plates (Becton Dickinson, Oxnard, CA) coated with
target antigen at a concentration of 20 ug/well in PBS. The
plates were coated overnight at room temperature, rinsed,
blocked with 1% BSA for 2 hours at 37°C, incubated with
109–1012 phage particles for 90 minutes at room temper-
ature, washed and incubated with HRP anti-M13 mono-
clonal conjugate (Pharmacia Biotech, Piscataway, NJ) at a
concentration of 1:5000 for 30 minutes at room tempera-
ture. The reaction was developed with substrate solution
(100 ul/well TMB (KPL, Gaithersburg, MD) in 100 mM
sodium acetate, pH 6.0. Fifty μl of 0.18 M sulphuric acid
was used to stop the reaction, and the OD was read at 650
nm and 450 nm using a Molecular Devices microplate
reader.
Expression of single chain antibodies in soluble form
The pHEN clones were infected into HB2151 and induced
with IPTG to yield soluble antibody fragments that were
identified on SDS polyacrylamide gels [6]. Eluted phage
(105 transforming units) were infected into 200 ul of
exponentially growing HB2151 bacteria for 30 minutes at
37°C, and plated on TYE plates with 100 ug/ml ampicillin
and 1% glucose. Single colonies were grown to log phase
in 2XTY containing ampicillin and 0.1% glucose and
induced with IPTG at a final concentration of 1 mM. Bac-
teria were grown overnight at 30°C, spun at 1800 × g for
10 minutes, resuspended and quantitated using BIORAD
Quantity One Software, Version 4.0.3 (BIORAD, Her-
cules, CA). Soluble single chain antibodies were used in
inhibition ELISA assays to measure binding affinity and
flow cytometry assays to measure the ability of these
clones to block human xenoantibody binding to pig
endothelial cells [60,61].
Flow cytometry
Flow cytometric analysis was conducted to measure the
ability of soluble single chain antibodies to block xenoan-
tibody binding to pig xenoantigens on endothelial cells.
Pig cells (1 × 106) were preincubated (blocked) with 500
ng of soluble single chain antibodies in germline or
mutated configurations for one hour at 4°C. These sam-
ples were then incubated with serum samples obtained
from normal humans at a dilution of 1/20 for 30 minutes
at 4°C. The cells were then washed and incubated with
100 ul of FITC-conjugated mouse anti-human IgG or IgM
at a 10 ng/ul dilution (Serotec, Cambridge, England) to
detect binding of human natural antibodies to pig
endothelial cells [61]. Binding of the IB4 lectin (100 ul of
a 1:100 dilution, 1 mg/ml stock) was used to detect levels
of the α-gal epitope expressed on pig cells in the presencePage 15 of 19
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orescence was read on a FACScan (Becton Dickinson).
Flow cytometric cytotoxicity assay
This assay measures antibody-mediated, complement-
dependent cytotoxicity and was used to determine
whether blocking of human natural antibody binding to
pig cells was associated with a reduction and/or elimina-
tion of complement-mediated cytoxocity [62]. PAEC were
incubated with human serum at a 1/20 dilution for 30
minutes, followed by the addition of rabbit complement
to each tube and incubation for one hour. Propidium
iodide was added to the samples which were incubated for
5 minutes, then washed with PBS containing 0.2% azide.
The samples were then ready to be acquired by the FACS-
can. The uptake of propidium iodide was indicative of cell
death.
Site-directed mutagenesis
Site-directed mutagenesis was done by overlap extension
PCR [63]. The 71A immunoglobulin gene encoding the
xenoreactive IGHV3-11 antibody in post-transplant sam-
ples was used as template DNA. The primers JH3XH01
and VH3BACKSfi, 50 forward (TTTCAGACATTAGTAG-
TAGTGGT) and 50 reverse (ACCACTACTACTAATGTCT-
GAAA) were used to allow the substitution of Y (Tyrosine)
with D (aspartic acid) in the CDR2 region of the xenoan-
tibody. The CDR1 mutation was introduced using the
primers 31 forward (TTAGTAGCTACTACATGAGCTGG)
and 31 reverse (CCAGCTCATGTAGTAGCTACTAA). This
allows the substitution of an S (Serine) in place of D
(Aspartic acid) in position 31. The PCR conditions
included one cycle of 94°C for five minutes and 30 cycles
of 94°C for 30 sec, 60°C for 30 sec and 72°C for 30 sec,
then one cycle of 72°C for seven minutes. PCR products
were run on an agarose gel to confirm the presence of a
product of correct molecular weight.
ELISA
Soluble single chain antibodies were tested by ELISA for
binding to purified gal di, tri and pentasaccharide (Dextra
Laboratories, UK) [60,61]. ELISA plates (MAXIsorb,
Nunc) were coated overnight at 4°C with 50 ul of purified
gal saccharide at a concentration of 5 ug/ml in bicarbo-
nate buffer pH 9.6. Plates were washed and blocked with
0.5% Tween 20 in PBS for 1 hour prior to the addition of
single chain antibodies in concentrations ranging from
0.1–100 ng/well. Single chain antibodies were incubated
with the saccharide for 1.5 hours prior to washing and the
addition of anti-hexahistidine antibody at a dilution of 1/
500 for 30 minutes. Plates were washed 3 times, substrate
was added followed by stop solution, and plates were read
at 405 nm.
Inhibition ELISA
Plates were precoated with gal pentasaccharide and
blocked as described above. Dilutions of single chain anti-
bodies demonstrated to result in 75% of maximum OD
were mixed with soluble antigen (purified gal pentasac-
charide) at concentrations ranging from 0.3–300 ug/ml
overnight at 4°C prior to transferring the mixture to the
antigen-coated ELISA plate [64]. The mixture was incu-
bated for 2 hours at room temperature prior to the addi-
tion of human natural antibodies obtained from normal
human serum at a concentration of 1/20. The plates incu-
bated with human natural antibodies were washed and
peroxidase conjugated goat anti-human IgG at a dilution
of 1/5000 or goat anti-human total Ig at a dilution of 1/
2500 was added. Plates were washed, developed and read
at 405 nm.
Statistics
The experiments involving antibody binding studies were
repeated a minimum of three times, and samples were run
in duplicate for each experimental timepoint. The data
presented include the standard deviation of the mean.
DNA sequencing
Single chain antibody clones and immunoglobulin gene
clones were sequenced using the ALFexpress automated
DNA sequencer and the Autocycle sequencing kit (Phar-
macia Biotech, Alameda, CA). pHEN vector-specific prim-
ers FOR Link Seq(GCC ACC TCC GCC TGA ACC) and
pHEN-SEQ (CTA TGC GGC CCC ATTCA) were used to
sequence the heavy and light chains cloned into these vec-
tors. Immmunoglobulin gene clones were sequenced
using the M13 universal primer 5'(cy5) GTAAAACGACG-
GCCAGT-3' and M13 reverse primer 5'(cy5)
AACAGCTATGACCATG-3.'
The closest germline genes were identified by BLAST [65].
Molecular modeling
Swiss-Model and Predict Protein are internet-based tools
for automated comparative protein modeling. They were
used to run a homology model search [66] to find a heavy
chain model with a structure similar to IGHV3-11 that has
been established by x-ray diffraction. The 1DEE PDB file
entry is an IgM heavy chain that is 90% similar to the
human xenoantibody cloned in our laboratory that was
used for the computer-simulated model. This structure
was selected because backbone structural error was not
introduced by insertions or deletions of amino acids using
this antibody as a template for the IGHV3-11 heavy chain
model. The IGHV3-11 heavy chain model was created
using the IDEE antibody as a template and Hyperchem
software (Hypercube, Boulder, CO) for the generation of
the homology model. The sequence/structure compatibil-
ity of the xenoantibody model with the 1DEE sequencePage 16 of 19
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dimensional profile analysis. The profile comparison
indicated a high level of overall compatibility of the
amino acid sequence with its modeled three dimensional
structure, and the absence of significant local ambiguities.
The crystal water molecules generated from coordinates
identified in 1DEE were placed in the corresponding
regions of the xenoantibody model. Energy minimization
was used to relax the contacts. We created models of
xenoantibody/gal interaction (gal di, tri and pentasaccha-
ride) using DOCK 4.0 software[67] and Autodock (Arthur
Olson, Molecular Graphics Lab, La Jolla, CA) for geomet-
ric docking simulation [33]. Select amino acids scored as
key contact sites using this model were modified using
site-directed mutagenesis in vitro to test the validity of the
models.
Genebank listing
Nucleic acid sequences have been deposited in Genebank
and are listed as assession numbers [Genbank:
AY994517–AY994523] for the light chain sequences and
[Genbank: AY986385–AY986390] for the VH4 sequences.
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